Neogen Corporation Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Neogen Corporation (NEOG) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$60.79 million for the 9-month period ending 2018-02-28, per its 10-Q filed 2018-03-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-03-29
- Neogen Corporation net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-02-28 was -$4.57M.
- Neogen Corporation net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-11-30 was -$16.34M.
- Neogen Corporation net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-08-31 was -$39.88M.
- Neogen Corporation net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-05-31 was -$2.95M.
- Neogen Corporation net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$62.14M.
- Neogen Corporation net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$61.15M.
- Neogen Corporation net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$28.45M.
- Neogen Corporation net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$51.29M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-02-28 | -$4.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-03-29 | -$20.91M derived: sum of 2 quarters · filed 2018-03-29 | -$60.79M 10-Q · filed 2018-03-29 | -$63.73M derived: sum of 4 quarters · filed 2018-03-29 |
| 2017-11-30 | -$16.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-01-05 | -$56.22M 10-Q · filed 2018-01-05 | -$59.17M derived: sum of 3 quarters · filed 2018-01-05 | -$108.41M derived: sum of 4 quarters · filed 2018-03-29 |
| 2017-08-31 | -$39.88M 10-Q · filed 2017-09-29 | -$42.83M derived: sum of 2 quarters · filed 2017-09-29 | -$92.07M derived: sum of 3 quarters · filed 2018-03-29 | -$98.07M derived: sum of 4 quarters · filed 2018-03-29 |
| 2017-05-31 | -$2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2017-07-28 | -$52.19M derived: sum of 2 quarters · filed 2018-03-29 | -$58.19M derived: sum of 3 quarters · filed 2018-03-29 | -$62.14M 10-K · filed 2017-07-28 |
| 2017-02-28 | -$49.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-03-29 | -$55.24M derived: sum of 2 quarters · filed 2018-03-29 | -$59.19M 10-Q · filed 2018-03-29 | -$82.39M derived: sum of 4 quarters · filed 2018-03-29 |
| 2016-11-30 | -$6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-01-05 | -$9.95M 10-Q · filed 2018-01-05 | -$33.14M derived: sum of 3 quarters · filed 2018-01-05 | -$46.19M derived: sum of 4 quarters · filed 2018-01-05 |
| 2016-08-31 | -$3.95M 10-Q · filed 2017-09-29 | -$27.14M derived: sum of 2 quarters · filed 2017-09-29 | -$40.19M derived: sum of 3 quarters · filed 2017-09-29 | -$28.62M derived: sum of 4 quarters · filed 2017-09-29 |
| 2016-05-31 | -$23.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-07-28 | -$36.24M derived: sum of 2 quarters · filed 2017-07-28 | -$24.68M derived: sum of 3 quarters · filed 2017-07-28 | -$61.15M 10-K · filed 2017-07-28 |
| 2016-02-29 | -$13.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-03-31 | -$1.48M derived: sum of 2 quarters · filed 2017-03-31 | -$37.95M 10-Q · filed 2017-03-31 | -$44.15M derived: sum of 4 quarters · filed 2017-07-28 |
| 2015-11-30 | $11.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-12-29 | -$24.91M 10-Q · filed 2016-12-29 | -$31.10M derived: sum of 3 quarters · filed 2017-07-28 | -$34.72M derived: sum of 4 quarters · filed 2017-07-28 |
| 2015-08-31 | -$36.47M 10-Q · filed 2016-09-30 | -$42.67M derived: sum of 2 quarters · filed 2017-07-28 | -$46.28M derived: sum of 3 quarters · filed 2017-07-28 | -$63.60M derived: sum of 4 quarters · filed 2017-07-28 |
| 2015-05-31 | -$6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-07-28 | -$9.81M derived: sum of 2 quarters · filed 2017-07-28 | -$27.13M derived: sum of 3 quarters · filed 2017-07-28 | -$28.45M 10-K · filed 2017-07-28 |
| 2015-02-28 | -$3.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-03-31 | -$20.93M derived: sum of 2 quarters · filed 2016-03-31 | -$22.26M 10-Q · filed 2016-03-31 | -$36.74M derived: sum of 4 quarters · filed 2016-07-29 |
| 2014-11-30 | -$17.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-01-08 | -$18.64M 10-Q · filed 2016-01-08 | -$33.13M derived: sum of 3 quarters · filed 2016-07-29 | -$43.22M derived: sum of 4 quarters · filed 2016-07-29 |
| 2014-08-31 | -$1.33M 10-Q · filed 2015-09-30 | -$15.81M derived: sum of 2 quarters · filed 2016-07-29 | -$25.91M derived: sum of 3 quarters · filed 2016-07-29 | -$35.14M derived: sum of 4 quarters · filed 2016-07-29 |
| 2014-05-31 | -$14.48M derived: 10-K 12 month − 10-Q 9 month · filed 2016-07-29 | -$24.58M derived: sum of 2 quarters · filed 2016-07-29 | -$33.81M derived: sum of 3 quarters · filed 2016-07-29 | -$51.29M 10-K · filed 2016-07-29 |
| 2014-02-28 | -$10.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-01 | -$19.32M derived: sum of 2 quarters · filed 2015-04-01 | -$36.81M 10-Q · filed 2015-04-01 | |
| 2013-11-30 | -$9.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-30 | -$26.71M 10-Q · filed 2014-12-30 | ||
| 2013-08-31 | -$17.48M 10-Q · filed 2014-09-30 | |||
| 2013-05-31 | -$37.95M 10-K · filed 2015-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |